InvestorsObserver
×
News Home

What is the Market's View on Regeneron Pharmaceuticals Inc (REGN) Stock's Price and Volume Trends Monday?

Monday, January 24, 2022 04:03 PM | InvestorsObserver Analysts

Mentioned in this article

What is the Market's View on Regeneron Pharmaceuticals Inc (REGN) Stock's Price and Volume Trends Monday?

Regeneron Pharmaceuticals Inc (REGN) stock has gained 1.13% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Regeneron Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on REGN!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With REGN Stock Today?

Regeneron Pharmaceuticals Inc (REGN) stock is trading at $622.22 as of 3:58 PM on Monday, Jan 24, a gain of $0.82, or 0.13% from the previous closing price of $621.40. Volume today is 839,252 compared to average volume of 766,670. The stock has traded between $601.25 and $623.54 so far today. To see InvestorsObserver's Sentiment Score for Regeneron Pharmaceuticals Inc click here.

More About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently. Click Here to get the full Stock Report for Regeneron Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App